MedTrace Logo

Radiotherapy Dose Complement in the Treatment of Hypoxic Lesions Patients With Stage III Non-small-cell Lung Cancer

NCT01576796 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2016-07-28

No results posted yet for this study

Summary

This study will assess the efficacy and safety of a radiotherapy dose complement (boost) in the treatment of hypoxic lesions, measured by F-miso PET/CT, in patients with stage III NSCLC not amenable to surgery and candidate for chemoradiotherapy.

Preliminary studies in head and neck cancers have demonstrated the feasibility and support the medical benefit of this novel approach.

The aim of the study is to assess the efficacy and safety of a radiotherapy dose complement (boost) in this difficult medical condition for which only limited treatment options are available.

Conditions

  • Stage III Non-small-cell Lung Cancer

Interventions

RADIATION

Radiotherapy

No additional dose (patients negative F-miso) * Radiation therapy is conducted under standard conditions of conformal radiotherapy: * The total dose was 66-70 Gy delivered in daily fractions of 2 Gy, 5 days a-week With additional dose (patients positive for F-miso) The dose in the PTVmiso increased until the maximum tolerable radiation by the lung.

Sponsors & Collaborators

  • Centre Henri Becquerel

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2016-03-31
Completion
2017-06-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01576796 on ClinicalTrials.gov